IMU and UK Biobank to generate the world’s most detailed, large-scale picture of the human immune system for advancing research into health and disease
IMU Biosciences (‘IMU or the ‘Company’), a biotechnology company using its High Definition Immunology™ platform to better understand the immune system and drive a shift in how we understand, diagnose, and treat disease, has today announced a new collaboration with UK Biobank to generate large-scale multi-omic immune profiling data from 80,000 blood samples collected from UK Biobank participants.
IMU Biosciences and Eurofins Transplant Genomics Form Strategic Partnership to Advance Transplant-Related Clinical Development Programmes
IMU Biosciences, a biotechnology company using its High Definition (“HD”) Immunology™ platform to decode the immune system and transform how we understand, diagnose, and treat disease, and Eurofins Transplant Genomics, a leading provider of laboratory services focused on post-transplant monitoring, today announced a licensing agreement that gives Eurofins Transplant Genomics exclusive access to IMU’s proprietary HD Immunology platform for transplant-related clinical development programmes.
IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision MedicineIMU Biosciences, a biotechnology company decoding the immune system to pioneer a paradigm shift in how we understand, diagnose, and treat disease, and Waters Corporation (
NYSE: WAT) today announced a strategic partnership to accelerate the development of IMU’s next-generation AI-powered High Definition (HD) Immunology platform.
IMU Biosciences announces oversubscribed financing round, bringing its Series A to over $53M as it accelerates its work to decode the immune system with unprecedented resolution and scale, to transform how we understand, diagnose and treat disease
IMU Biosciences (‘IMU or the ‘Company’), a biotechnology company decoding the immune system to pioneer a paradigm shift in how we understand, diagnose and treat disease, has successfully brought its Series A to over $53 million (£40 million) in an oversubscribed financing round, co-led by IQ Capital and Molten Ventures, and supported by The British Business Bank and Meltwind alongside existing investors.
